Daewon Pharmaceutical's Phase 3 Success for 'Fodopraazan'; Competition Heats Up in Expanding P-CAB Market
Predicted impact: Medium
Phase 3 success already reported and priced in; drug is key to a company worth about 0.17T won.
Daewon Pharmaceutical대원제약
003220 · KOSPI · ₩003220 · 대원제약
₩7,700▼ ₩60 (0.77%)End-of-day · Oct 29, 2026 · End-of-day prices.
[Stock Spotlight] Daewon Pharmaceutical strengthens on phase 3 success of new gastroesophageal reflux drug
Predicted impact: Medium
Phase 3 success for new drug; stock jumped about 16%, commercial size not yet quantified.
Daewon Pharmaceutical shares up 16% on successful P-CAB phase 3 trial [Why Bio]
Predicted impact: Medium
Phase 3 success for P-CAB drug; stock already surged 16%, but approval filing still pending.
Daewon Pharmaceutical's P-CAB new drug 'Fadoprazan' succeeds in Phase 3 trial; plans to file for product approval within the year
Predicted impact: Medium
Phase 3 success and approval filing plan are meaningful but already covered.
Daewon Pharmaceutical's P-CAB new drug 'Fadoprazan' proves efficacy and safety in Phase 3 clinical trial
Predicted impact: Medium
Phase 3 success for a drug is significant but was already reported and surged shares.
Daewon Pharmaceutical surges over 10% in aftermarket trading
Predicted impact: Low
Oral obesity drug data and a 10% aftermarket jump; drug data already reported in the last 14 days.
[Obituary] Mother of Lee Gil-ho (Executive Director, Daewon Pharmaceutical) passed away
Predicted impact: Low
Family bereavement notice for an executive; no business impact.
Daewon Pharmaceutical also hits the accelerator on oral obesity drug development
Predicted impact: Low
Oral obesity drug development updates repeat earlier clinical news; early-stage, no revenue size given.
Daewon Pharmaceutical presents oral platform diabetes and obesity drug clinical data in the US
Predicted impact: Low
Early-stage US research presentation for an oral diabetes drug; no revenue impact yet.
Daewon Pharmaceutical: 'Oral Obesity Drug Candidate Achieves Three Times Higher Absorption Rate'
Predicted impact: Low
Preclinical oral obesity candidate absorption improvement; early stage with small revenue relevance.
Daewon Pharmaceutical accelerates development of oral obesity treatment, with drug exposure up to 3.14 times
Predicted impact: Low
Daewon Pharmaceutical Develops Oral Obesity Drug Absorption Technology... "Up to 3.14 Times Better Than Rybelsus"
Predicted impact: Low
Oral obesity drug absorption tech; early research with no revenue size.
Daewon Pharmaceutical Presents Oral Diabetes and Obesity Drug Research in US; Plans to File for Phase 1 in Korea Next Year
Predicted impact: Low
Early-stage US research presentation for an oral diabetes drug; no revenue impact yet.
[Obituary] Lee Chang-su (Director, Pharmaceutical Division 1, Medical Drugs Business Unit, Daewon Pharmaceutical) — mother-in-law passed away
Predicted impact: Low
Daewon Pharmaceutical's 'Magnesium King' Sells 50,000 Bottles One Month After Launch
Predicted impact: Low· Actual: −6.6% vs sector, volume 0.7× normal (5 trading days)
Product sales milestone of 50,000 bottles; small relative to company.
Also known as: Daewon Pharmaceutical / 대원제약 / 003220 / KRX:003220
Source: KRX statistical information